Research & Development: Page 35

  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Upfront

    Johnson & Johnson Announces 10-year Initiative to Help End Tuberculosis Johnson & Johnson has announced a comprehensive 10-year initiative in support of the United Nations’ Sustainable Development Goal target of ending the TB pandemic by 2030. With the goal of saving an estimated 1.8 mill...

    By PharmaVoice Team • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    HealthTech

    Nanomedicine Zeros In On Triple Negative Breast Cancer Cells Trend Watch: From Breast Cancer to Asthma, Healthtech Tools Develop Care Solutions Researchers at George Washington University have shown that a technique of delivering a chemotherapy agent within specially designed nanoparticles can be...

    By PharmaVoice Team • Nov. 15, 2018
  • cancer healthcare Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Oncology

    As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

    By PharmaVoice staff
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    2019 Trend Tracking

    In this special 2019 Year in Preview issue, more than 100 PharmaVOICE thought leaders address 10 trends that are expected to be part of the changing landscape in the year ahead. These areas of focus cover a variety of disparate topics that range from molecule to market in keeping with our publish...

    By Taren Grom • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Looking Forward To

    AI Adoption Richard Davies VP, Solution Expert, CluePoints The application of artificial intelligence and machine learning within the R&D process to guide disparate stakeholders through the planning and execution of clinical trials through targeted risk management is both a current capability...

    By Taren Grom • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Trend: 3D and Bioprinting

    The bioprinting field continues to grow and mature. With the evolution of the technology, experts believe even broader applications are on the horizon, providing patients with fully functioning cells — and even organs — that have been created through bioprinting processes. “All of us can envision...

    By Denise Myshko • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Trend: Advanced Diagnostics and Precision Medicine

    Healthcare is moving increasingly toward personalized approaches — tailoring treatment based on each patient’s unique disease. Precision medicine is well-established in oncology, with many cancers now characterized by their unique genomic alterations. In the past few years, the Food and Drug Admi...

    By PharmaVoice Team • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Trend: Rare Disease Innovation

    It’s been almost 120 years since the word gene was coined. Today, researchers are well on their way to manipulating genes to treat diseases. With only about 400 approved treatments for more than 7,000 rare diseases — 80% of which are caused by gene mutations — scientific advances are enabling gen...

    By PharmaVoice Team • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Trend: R&D Modeling and Simulation

    The Food and Drug Administration for several years has been advocating for the use of computer modeling and simulation as a way to accelerate access to new therapies. First proposed by the agency in 2011 as part of its Critical Path Initiative, modeling and simulation are gaining traction, with t...

    By Denise Myshko • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    Looking to Simplify Your Safety Notifications Process? Consider a Cross-Trial SaaS Solution Why new centralized SaaS solutions make more sense than ever before A traffic-light is out of service during rush hour in a busy city intersection. To prevent accidents, a police officer is there directing...

    By Brian Fisher • Nov. 15, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Innovation meets the market There are 977 clinical trials under way for products that use regenerative medicine technology. There are more than 150 gene therapy drugs in Phase I, II and III clinical trials in progress as rare disease research enters into a new era of patient-focused innovation. A...

    By Taren Grom • Oct. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    Discovered by AI Dr. Vimal Mehta, CEO of BioXcel Therapeutics, talks about the company’s clinical candidates identified through an artificial intelligence and machine-learning platform. BioXcel Therapeutics is showing that investments in artificial intelligence (AI) and machine learning can pay o...

    By Dr. Vimal Mehta • Oct. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Agencies Pay It Forward

    In an open letter to CEOs earlier this year, BlackRock CEO and financial wizard Larry Fink outlined the need for companies to start focusing on the world outside their walls and find a way to serve a larger societal purpose. His thought process is that while focusing on building revenue, companie...

    By PharmaVoice Team • Oct. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Trial Sites and Patient Diversity

    Having a diverse patient population in clinical trials is important because medicines affect people differently based on age, sex, and race. Biologic, genetic, and even cultural differences between patients can impact how a treatment will actually work in practice. Industry experts say the racial...

    By Denise Myshko • Oct. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Red Zone: Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites

    Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit" sites and returned to them f...

    By WCG Clinical Services • Oct. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    In the People Business According to PhRMA, 74% of the medicines in clinical development are potentially first-in-class medicines, meaning they represent a possible new pharmacological class for treating a medical condition. Furthermore, PhRMA reports that there are 822 projects, defined as unique...

    By Taren Grom • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Innovator's Corner

    A Potential Treatment for Autism Kevin Sanders, M.D., Principal Medical Director of the Autism Program at Roche, talks about the company’s research program for balovaptan, which is being investigated to help improve social interaction and communication in people with autism. Autism, a lifelong de...

    By PharmaVoice Team • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Last Word

    Innovation: As Many Questions As Answers John Nosta, President and Founder of Nosta Labs, challenges the status quo in discussing the state of innovation in the industry. PV: Can the pharmaceutical industry evolve based on its current organizational structure and incentives? Nosta: No, I don’t th...

    By John Nosta • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Agency Executive Roundtable

    Heavy is the Crown Without a doubt talent — recruitment, retention, and engagement — is the biggest challenge our agency executives face today. At the same time, technology, ideation, shared value, and time are also top of mind. Sharon Callahan. TBWA\WorldHealth. The first challenge that comes to...

    By PharmaVoice Team • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Brain Wave: Breakthroughs Bring New Hope to CNS

    In February 2018, FDA Commissioner Scott Gottlieb, M.D., emphasized the agency’s commitment to advancing the development of novel treatments for neurological conditions. His statement recognized the uneven progress made in certain diseases and pinpointed the complex nature of neurological conditi...

    By Kim Ribbink • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Red Zone: Avoid Enrollment Pitfalls by Engaging with Best-Fit Sites

    Perhaps the single most important consideration in selecting a site is whether it can make its enrollment. Many don’t; in fact, 20-25 percent of all clinical studies close because they fail to meet enrollment targets.1 For decades, sponsors have found their “best fit" sites and returned to them f...

    By WCG Clinical Services • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Speak Out

    Medical affairs is in the midst of a transformation. The dynamics of the healthcare industry, the complexity of new science, and the breadth and sophistication of communication channels that physicians have available for accessing information, are expanding the role of medical affairs and reshapi...

    By PharmaVoice Team • Sept. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    For Their Transformative Inspiration and Influence Transformation is easy to define: a thorough or dramatic change in form or appearance. Transformation is much harder to achieve. For this special — and my favorite — issue we asked this year’s PharmaVOICE 100 to provide a short response to the st...

    By Taren Grom • Aug. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Change Agents

    Dr. Patrice Matchaba For Advancing the Quest for Global Access Title: Group Head of Global Health & Corporate Responsibility Company: Novartis AG Education: MD, University of Zimbabwe; Harvard Business School Program for Management Development A number of years ago, Dr. Patrice Matchaba’s mot...

    By PharmaVoice Team • Aug. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Clinical Experts

    Nariman Nasser For Creating Opportunities for Sites Title: VP, Site Engagement Company: Continuum Clinical Education: BS Microbiology, Arizona State University Hobbies: Swimming, biking, snowboarding, and anything outdoors that provides an adrenaline rush Associations: SoCRA, DIA, ACRP Social Med...

    By PharmaVoice Team • Aug. 1, 2018
  • Image attribution tooltip
    PharmaVoice Team/PharmaVoice
    Image attribution tooltip

    Letter from the Editor

    Transforming for the Future By definition transformation means a thorough or dramatic change in form or appearance. Our thought leaders in this month’s cover story believe such a reshaping is necessary for the industry to have success in the future as biopharma companies must meet the business ch...

    By Taren Grom • June 1, 2018